VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ABT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ABTAbbott Laboratories
$104.71$182.4B
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksABTCash Flow

Abbott Laboratories (ABT) Cash Flow Statement

30Y historyFree accessUpdated daily

Operating cash flow to net income ranged widely from 0.31 to 2.68, and the latest free cash flow margin of 9.4% against a $1.1B quarterly dividend outflow suggests shareholder distributions are absorbing much of the cash generated in weaker quarters.

Income StatementBalance SheetCash FlowRatios

ABT Cash Flow Statement

Annual statement

ABT Cash Flow Statement

Abbott Laboratories (ABT) cash flow statement — 30-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations8.86B9.57B8.56B7.26B9.58B10.53B7.9B6.14B6.3B5.57B3.2B2.97B3.67B3.32B9.31B8.97B8.74B7.28B7.34B5.18B5.33B5.17B4.41B3.75B4.18B3.57B3.1B2.94B2.73B2.63B2.38B
Operating CF Margin %-21.58%20.4%18.1%21.95%24.45%22.83%19.23%20.6%20.34%15.36%14.54%18.15%15.21%23.36%23.09%24.84%23.65%24.87%20%23.71%23.16%22.4%19.04%23.65%21.9%22.55%22.29%21.9%22.12%21.63%
Operating CF Growth %-7.74%11.78%17.86%-24.21%-9.04%33.31%28.76%-2.6%13.11%73.9%7.99%-19.29%10.56%-64.31%3.84%2.68%20.08%-0.94%41.67%-2.73%2.99%17.39%17.66%-10.44%17.27%15.07%5.52%7.49%3.96%10.36%21.19%
Net Income4.7B6.52B13.4B5.72B6.93B7.07B4.5B3.69B2.37B477M1.38B1.58B2.28B2.58B5.96B4.73B4.63B5.75B4.73B3.61B1.72B3.37B3.18B2.75B2.79B1.55B2.79B2.45B2.33B2.09B1.88B
Depreciation & Amortization3.79B3.12B3.22B3.24B3.27B3.54B3.33B3.01B3.28B3.02B1.35B1.47B1.55B1.72B2.78B3.04B2.62B2.09B1.84B1.85B1.56B1.36B1.29B1.27B1.18B1.17B827.43M828.01M784.24M727.75M686.09M
Stock-Based Compensation735M664M673M644M685M640M546M519M477M406M310M292M246M262M433M383M387.18M366.36M347.01M46.33M136.47M9.74M-10.22M-7.66M11.72M000000
Deferred Taxes00000000293M-1.16B248M314M429M395M1.85T968.76B328.41B508.67B1.01B-4.77M-44.51M65.35M-70.22M28.79M2.62M000000
Other Non-Cash Items-217M65M482M126M215M55M425M247M32M912M1.43B-539M-342M-391M-1.85T-967.94B-327.97B-509.25B-545.03M744.45M2.51B194.38M508.76M194.91M227.84M1.49B-68.59M83.71M76.62M145.02M53.8M
Working Capital Changes-155M-803M-9.22B-2.48B-1.52B-771M-892M-1.33B-148M1.92B-1.51B-156M-490M-1.24B-1.86B1.07M658.78M-341.38M-39.69M-1.06B-548.06M173.94M-484.92M-496.82M-30.28M-641.9M-445.2M-419.96M-461.19M-338.46M-239.86M
Change in Receivables-682M-652M-691M-356M-68M-383M-924M-275M-190M-207M-177M-171M-195M-113M36M-670.15M-394.67M-387.75M-948.31M12.89M21.07M-158.98M75.44M40.57M-137.71M-279.17B-260.79M0000
Change in Inventory-538M195M-58M-232M-1.41B-456M-493M-593M-514M249M-98M-257M-297M-154M-417.05M-129.62M139.86M230.56M-257.48M131.32M104.65M-88.26M-285.33M7.01M-190.97M-184.95M-361.38M-147.78M-111.65M-98.96M-125.73M
Change in Payables0954M356M-760M420M1.29B1.77B220M747M615M-652M-742M-225M-436M-134.21M1.79B572.53M-374.71M569.06M-59.38M-80.09M-62.43M-99.93M-17.79M56.67M732.48B621.08M0000
Cash from Investing-22.3B-2.42B-2.34B-3.13B-1.74B-2.01B-2.21B-1.81B-1.36B-9.62B-248M406M-202M-3.93B-6.08B260.83M-12.19B-3.7B-2.09B-1.14B-11.4B-720.09M-3.92B-1.63B-1.88B-8.38B-617.66M-1.2B-1.42B-1.2B-1.96B
Capital Expenditures-2.1B-2.17B-2.21B-2.2B-1.78B-1.89B-2.18B-1.64B-1.39B-1.14B-1.12B-1.11B-1.08B-1.15B-1.8B-1.49B-1.02B-1.09B-1.29B-1.66B-1.34B-1.21B-1.29B-1.25B-1.3B-1.16B-1.04B-987.1M-1.24B-1.21B-949M
CapEx % of Revenue4.35%4.9%5.26%5.49%4.07%4.38%6.29%5.13%4.56%4.14%5.38%5.44%5.32%5.24%4.5%3.84%2.89%3.54%4.36%6.39%5.95%5.41%6.56%6.33%7.33%7.15%7.54%7.49%9.96%10.18%8.62%
Acquisitions-20.13B-105M1M-837M48M-53M16M-122M48M-8.44B-55M2.29B-3.32B-580M-1.23B-672.5M-9.43B-2.37B-250M0-7.92B-295.12M-2.33B-497.91M-586M-7.42B205M-217M-1.24B-1.21B-1.78B
Investments-------------------------------
Other Investing59M18M9M22M22M26M19M27M48M35M42M52M75M21M2.72M1.89B-1.89B-6.37M-75.06M-33.48M-25.71M14.6M14.43M66.47M16.57M-308.78B45.45M12.19M18.03M-8.21M19.1M
Cash from Financing9.99B-6.31B-5.4B-7.09B-7.64B-5.49B-2.78B-4.29B-10.39B-5.28B11.15B-2.24B-2.74B-6.7B716.09M-6.02B-1.09B1B-3.49B-2.31B3.62B-2.59B-438.32M-2.01B-2.31B4.62B-2.15B-1.43B-1.23B-1.31B-592.29M
Debt Issued (Net)15.53B-1.61B-537M-2.48B-699M-248M-50M-1.6B-8.45B-1.91B13.15B1.15B766M1.79B4.41B-3.98B2.12B3.73B-1.24B-544.49M5.65B172.83M806M-467.93M-1.02B5.74B-672.77M-857.7M382.4M417.3M835M
Equity Issued (Net)-1.31B-497M-1.29B-1.23B-3.79B-2.3B-403M-718M-238M-477M-522M-2.24B-2.19B-1.6B-2.36B891.75M-866.83M-826.35M-1.08B191.01M-251.72M-1.08B-344.55M-22.58M137M152.06M-329.29M434.2M-723.9M-896.7M-699.2M
Dividends Paid-4.32B-4.12B-3.84B-3.56B-3.31B-3.2B-2.56B-2.27B-1.97B-1.85B-1.54B-1.44B-1.34B-882M-3.18B-2.94B-2.67B-2.41B-2.17B-1.96B-1.78B-1.69B-1.6B-1.52B-1.43B-1.27B-1.15B-1B-891.7M-809.6M-728.1M
Share Repurchases-1.54B-893M-1.29B-1.23B-3.79B-2.3B-403M-718M-238M-827M-522M-2.24B-2.19B-1.6B-2.36B-77.01M-866.83M-826.35M-1.08B-1.06B-754.5M-1.3B-499.75M-97.62M0-17.36M-464.86M0-876.3M-1.05B-808.8M
Other Financing100M-82M264M167M167M255M234M298M271M-1.05B53M297M29M-6B1.33B-96K328.41M508.67M1.01B00000000-26K000
Net Change in Cash-3.46B906M720M-2.99B83M2.96B2.98B16M-5.56B-9.21B13.62B938M588M-7.33B3.99B3.16B-5.16B4.7B1.66B1.94B-2.37B1.67B230.5M290.67M47.07M-256.84M306.12M292.86M78.21M119.81M-170.99M
Free Cash Flow7.65B7.39B6.35B5.06B7.8B8.65B5.72B4.5B4.91B4.43B2.08B1.86B2.6B2.18B7.52B7.48B7.72B6.19B6.06B3.53B3.99B3.97B3.12B2.5B2.89B2.4B2.06B1.95B1.49B1.42B1.43B
FCF Margin %15.87%16.68%15.14%12.61%17.88%20.08%16.54%14.1%16.04%16.19%9.98%9.1%12.83%9.97%18.86%19.25%21.95%20.11%20.51%13.61%17.76%17.76%15.83%12.7%16.32%14.76%15.01%14.8%11.94%11.94%13.01%
FCF Growth %10.64%16.44%25.54%-35.17%-9.76%51.08%27.26%-8.32%10.62%113.02%12.18%-28.56%19.23%-71.02%0.54%-3.14%24.81%2.14%71.69%-11.62%0.62%27.3%24.67%-13.4%20.12%16.45%5.81%30.88%5.01%-0.97%-27.09%
FCF per Share4.404.233.632.894.424.833.202.532.772.541.401.231.701.384.724.764.963.983.882.262.602.541.981.591.831.531.321.250.950.900.91
FCF Conversion (FCF/Net Income)1.63x1.47x0.64x1.27x1.38x1.49x1.76x1.66x2.66x11.68x2.29x0.67x1.61x1.29x1.56x1.90x1.89x1.27x1.50x1.44x3.10x1.53x1.36x1.36x1.50x2.30x1.11x1.20x1.17x1.26x1.27x
Interest Paid00604M662M563M544M549M677M845M917M181M166M146M148M576M545M580.17M00000000000000
Taxes Paid001.72B1.48B1.86B1.94B970M930M740M570M620M631M448M1.04B1.37B1.78B809.71M00000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Quarterly cash flow volatility and acquisition outflows

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Cash Conversion Swings Obscure Earnings Quality

According to the reported quarterly cash flow statements, ABT's operating cash flow to net income ratio ranged from 0.31 in Q4 2024 to 2.68 in Q2 2026, a dispersion that suggests reported earnings are heavily affected by working capital timing rather than steady underlying cash generation across the ten quarters reviewed.

The Q4 2024 ratio of 0.31, driven by a roughly $8.4B working capital outflow against $9.2B of net income, indicates that the reported profit that quarter was largely offset by balance sheet movements that may warrant further investigation. Conversely, the elevated ratios in 2026 Q2 and 2025 Q4 appear to reflect working capital release rather than structurally superior earnings quality. Investors should monitor whether the trailing average conversion settles near the 1.2 to 1.9 range seen in most quarters, which would be more consistent with the company's reported profitability profile.

Free Cash Flow Margins Remain Volatile

Based on reported figures, ABT's free cash flow margin moved between 8.2% and 22.9% across the ten quarters, with the most recent quarter at 9.4%, a range that suggests cash generation is more sensitive to timing items than to a stable operating run-rate.

The compression to 9.4% in 2026 Q3 from 22.9% in 2026 Q2 reflects a working capital swing of roughly -$576M against a rebound in operating cash flow, which implies the headline FCF figure may overstate or understate sustainable generation depending on the quarter. Averaging across the window produces a mid-teens margin that appears more representative of the underlying business than any single quarter. The trajectory warrants monitoring for whether the 2026 Q2 spike was a one-time release or the start of a sustained step-up.

Capital Intensity Stays Modest Relative to Revenue

As reported in the quarterly cash flow statements, ABT's capital expenditures ran between 3.6% and 6.6% of revenue across the period, with recent quarters clustering near 3.6% to 3.9%, a level that appears light for a diversified medical device and diagnostics manufacturer.

Capex of roughly $400M to $720M per quarter against D&A of approximately $730M to $810M in most periods indicates the company has been spending close to, and at times below, its depreciation base, which may suggest either efficient utilization of existing plant or underinvestment in replacement capacity. The 2026 Q1 and Q3 readings near $400M to $510M sit below the 2024 and 2025 run-rate, and investors should watch whether that reduction reflects completed manufacturing build-outs or deferred maintenance needs.

Dividend Commitment Dominates Recurring Outflows

According to the reported cash flow data, ABT paid roughly $958M to $1.1B in dividends in each quarter of the window, a steady outflow that consumed much of free cash flow in weaker quarters such as 2026 Q1 and 2025 Q1.

In quarters where FCF fell to roughly $916M to $933M, dividends absorbed nearly all of the generated cash, leaving little residual capacity for buybacks or debt reduction without external funding. Acquisition outflows were lumpy, including an unusually large $19.8B figure in 2026 Q1 that appears to be a major transaction and warrants further investigation into its strategic rationale and financing. The pattern suggests capital allocation is weighted toward the dividend and episodic large acquisitions rather than a predictable repurchase program.

Cumulative Cash Gap Reflects Working Capital Noise

Based on the ten reported quarters, cumulative operating cash flow appears to exceed cumulative net income, but this gap is heavily influenced by a single $8.4B working capital outflow in Q4 2024 that may distort any simple long-run comparison.

Excluding the Q4 2024 working capital distortion, operating cash flow tracked net income at a ratio that appears comfortably above 1.0 in most periods, which suggests the underlying business generates cash in excess of reported earnings after non-cash charges such as D&A. The divergence is therefore less a signal of earnings inflation than of timing volatility in receivables, inventory, and payables. Investors should avoid drawing firm conclusions about earnings quality from any short window without extending the analysis across a full cycle.

Cash Flow Statement May Understate Structural Pressures

Based on reported figures, the bear case rests on operating margin compression to roughly 10% in the latest quarter alongside legal exposure accounting for about 32% of tracked risk factors, which may indicate cash generation is flattered by working capital timing that could reverse.

If the strong 2026 Q2 operating cash flow of $2.5B was supported by a $734M working capital release rather than durable earnings, the subsequent normalization seen in 2026 Q3 could represent the underlying run-rate rather than an anomaly. Litigation and product-related claims, particularly in pediatric nutrition, may not be fully reflected in the reported cash flow figures and warrant further investigation into any reserves or contingent payments. Investors should consider whether the dividend and episodic acquisition outflows remain sustainable if operating cash flow reverts toward the lower end of the observed range.

ABT — Frequently Asked Questions

Quick answers to the most common questions about buying ABT stock.

How much cash does Abbott Laboratories (ABT) generate from operations?

Abbott Laboratories (ABT) generated $9.57B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Abbott Laboratories's free cash flow?

Abbott Laboratories (ABT) generated $7.39B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Abbott Laboratories's capital expenditure (CapEx)?

Abbott Laboratories (ABT) spent $2.17B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Abbott Laboratories distribute cash to shareholders?

In 2025, Abbott Laboratories (ABT) returned $4.12B to shareholders via cash dividends and spent $893.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.